Dicynone pills 250 mg 100 pcs
Condition: New product
998 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Etamzilat
Release form
Pills
Composition
1 tablet contains: Active ingredients: etamzilat 250 mg. Excipients: anhydrous citric acid, corn starch, Povidone K25, magnesium stearate, lactose.
Pharmacological effect
Dicynone is a hemostatic, antihemorrhagic and angioprotective substance, normalizes the permeability of the vascular wall, improves microcirculation. Stimulates the formation of platelets and their release from the bone marrow. The hemostatic effect is due to the activation of the formation of thromboplastin at the site of damage to small vessels and the reduction of the formation of prostacyclin PgI2 in the vascular endothelium. does not affect the concentration of fibrinogen and prothrombin time. Doses of more than 2-10 mg / kg do not lead to greater severity of the effect. With repeated injections, thrombosis is enhanced. The angioprotective effect of Ditsinona is associated with its effect on the endothelium of capillaries and the main substances of the interendothelial spaces. Possessing antihyaluronidase activity and stabilizing ascorbic acid, prevents degradation and promotes the formation of large molecular weight mucopolysaccharides in the capillary wall, increases the resistance of capillaries, reduces their fragility, and normalizes permeability during pathological processes. Reduces the release of fluid and diapedes blood cells from the vascular bed, improves microcirculation. This angioprotective effect is manifested in the treatment of various diseases associated with primary or secondary disorders of the microcirculation process. Does not have hypercoagulable properties, does not contribute to thrombosis, does not have a vasoconstrictor action. Restores the diseased bleeding time. The normal parameters of the hemostasis system are not affected. Dicynone practically does not affect the composition of peripheral blood, its proteins and lipoproteins. Slightly increases the content of fibrinogen. Erythrocyte sedimentation rate may decrease slightly.In addition, it normalizes or reduces the pathologically increased permeability and capillary fragility.
Pharmacokinetics
Absorption and distribution After i / v administration of the drug at a dose of 500 mg Cmax is reached after 10 minutes and is 50 μg / ml. After ingestion, the drug is rapidly and almost completely absorbed. After taking the drug in a dose of 50 mg Cmax is reached after 4 hours and is 15 μg / ml. Etamzilat penetrates the placental barrier and is excreted in breast milk. Excretion About 72% of the administered dose is eliminated by the kidneys during the first 24 hours in an unchanged form. in the introduction of T1 / 2 is about 2 hours, after ingestion of T1 / 2 is about 8 hours
Indications
treatment of internal capillary bleeding of various etiologies, especially if the bleeding is caused by damage to the endothelium: prevention and treatment of bleeding during and after surgical operations on all well vascularized tissues in otorhinolaryngology, gynecology, obstetrics, urology, dentistry, ophthalmology and plastic surgery; different etiology and localization: hematuria, metrorrhagia, primary metrorrhagia, menorrhagia in women with intrauterine contraceptive and epistaxis, bleeding gums, prevention and treatment of diabetic microangiopathy (haemorrhagic diabetic retinopathy, recurrent hemorrhages into retina, hemophthalmus).
Contraindications
hypersensitivity to any of the ingredients; thrombosis; thromboembolism; acute porphyria; hemoblastosis. The drug should be prescribed with caution in the following cases: With thrombosis, a history of thromboembolism. When bleeding on the background of an overdose of anticoagulants.
Use during pregnancy and lactation
Use during pregnancy is possible only in cases where the potential benefit of therapy for the mother outweighs the possible risk to the fetus. If necessary, the appointment of the drug during lactation breastfeeding should be discontinued.
Dosage and administration
The optimal dose for adults: 10-20 mg Ditsinona per kg of body weight in 3-4 doses. Therefore, both for prophylaxis and for treatment, the dose is 1-2 pills or 1-2 ampoules (IM or IV) Ditsinona 3-4 times a day; in severe cases, 3 pills or 3 ampoules 3-4 times a day. Recommended dosage for children: 10-15 mg Ditsinona per kg of body weight per day, divided into 3-4 doses. Tablets should be taken with or after meals.
Side effects
heartburn; feeling of heaviness in the epigastric region; headache; dizziness; flushing of the face; mild transient decrease in systolic pressure; paresthesia of the lower extremities.
Overdose
Data overdose Dicynone not provided.
Interaction with other drugs
Perhaps a combination with aminocaproic acid and sodium menadione bisulfite.
special instructions
Before starting treatment, other causes of bleeding should be excluded. 1. Dicine's tablet contains 60.5 mg of lactose (the maximum daily dose of lactose should not exceed 5 g). It should not be prescribed to patients with congenital intolerance to glucose, lactase-deficient lapp (lactase deficiency in some ethnic groups of the North) or glucose-galactose malabsorption syndrome.